1-1 of 1
Andres Negro-Vilar, MD, PhD
Close
Sort by
Journal Articles

Phase III Study of Denileukin Diftitox (ONTAK®) To Evaluate Efficacy and Safety in CD25+ and CD25- Cutaneous T-Cell Lymphoma (CTCL) Patients.

Andres Negro-Vilar, MD, PhD, Zofia Dziewanowska, MD, Eric Groves, MD, PhD, Elyane Lombardy, MD, Victor Stevens, PhD
Journal: Blood
Blood (2006) 108 (11): 696.
https://doi.org/10.1182/blood.V108.11.696.696
Published: 2006